Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients
NCT ID: NCT00233597
Last Updated: 2022-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
230 participants
INTERVENTIONAL
2004-08-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
NCT00255437
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
NCT00255424
Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
NCT00236977
2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.
NCT00223977
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
NCT01114217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ferumoxytol or oral iron
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic hemodialysis.
* Stable supplemental EPO therapy.
* Baseline hemoglobin of ≤ 11.5 g/dl.
Exclusion Criteria
* Received another investigational drug or device within 30 days.
* Recent parenteral or oral iron therapy.
* Patients with active GI bleeding or acute bleeding within 4 weeks. Patients that have other causes of anemia.
* Major surgery within 30 days or anticipated or planned surgery during the study.
* Patients with active infections.
* Recent blood transfusions.
* Patients with known allergies to iron products.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AMAG Pharmaceuticals, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Tempe, Arizona, United States
Los Angeles, California, United States
Mountain View, California, United States
New Haven, Connecticut, United States
Hudson, Florida, United States
Tampa, Florida, United States
Augusta, Georgia, United States
Honolulu, Hawaii, United States
Gurnee, Illinois, United States
Hines, Illinois, United States
Baton Rouge, Louisiana, United States
Bethesda, Maryland, United States
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Columbus, Mississippi, United States
Jackson, Mississippi, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Albuquerque, New Mexico, United States
Brooklyn, New York, United States
Brooklyn, New York, United States
Brooklyn, New York, United States
Flushing, New York, United States
Mineola, New York, United States
New York, New York, United States
New York, New York, United States
Orchard Park, New York, United States
Springfield Gardens, New York, United States
Chapel Hill, North Carolina, United States
Portland, Oregon, United States
Lewistown, Pennsylvania, United States
Greenville, South Carolina, United States
Sumter, South Carolina, United States
Knoxville, Tennessee, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Alexandria, Virginia, United States
Chesapeake, Virginia, United States
Fairfax, Virginia, United States
Norfolk, Virginia, United States
Salem, Virginia, United States
Spokane, Washington, United States
Appleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005 Jul-Aug;25(4):400-10. doi: 10.1159/000087212. Epub 2005 Jul 28.
Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93. doi: 10.2215/CJN.02840608. Epub 2009 Jan 28.
Related Links
Access external resources that provide additional context or updates about the study.
National Kidney Foundation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
62745-5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.